Compare GLOB & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLOB | IRON |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2015 | 2020 |
| Metric | GLOB | IRON |
|---|---|---|
| Price | $46.55 | $64.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | $78.64 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 1.1M | 445.3K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.06 | N/A |
| Revenue Next Year | $5.30 | $283.52 |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.77 | $30.82 |
| 52 Week High | $142.25 | $99.50 |
| Indicator | GLOB | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 53.83 |
| Support Level | $41.39 | $57.79 |
| Resistance Level | $71.47 | $69.36 |
| Average True Range (ATR) | 2.16 | 2.76 |
| MACD | 0.61 | 0.92 |
| Stochastic Oscillator | 82.44 | 73.17 |
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.